Fig. 3.

Agonist induction of AMPK activity in A/I kidney cortex. Each immunoblot was sequentially probed with three antibodies to p-AMPKα (Thr¹⁷²), AMPKα₁, and GAPDH, as in Fig. 1. This series was performed at day 7 with treatment groups undergoing A/I. As with Fig. 1, the day 7 A/I kidneys exhibited a substantial decrease in AMPK activity relative to the normal animals. This reduction in AMPK activity was normalized by AMPK activation with metformin (MET) (A), or 5-aminoimidazole-4-carboxamide-1 riboside (AICAR) (B). Respective graphs are below the immunoblots for A and B. C: representative blot showing the correlation of p-AMPK with p-ACC at this 7-day time point to validate agonist induction of AMPK activity in A/I kidneys. Data are expressed as means ± SE. *P < 0.01 vs. normal. **P < 0.01 vs. A/I; n = 3.